Business
GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights
Reported third quarter 2025 revenues of $116.7 million with 65% year-over-year growth in exome and genome test revenue Accelerated exome and genome volume
About this update from Genedx Holdings Corp.
[{"type":"text","content":"\n\nReported third quarter 2025 revenues of $116.7 million with 65% year-over-year growth in exome and genome test revenue\n\n\n\nAccelerated exome and genome volume growth to 33% year-over-year\n\n\n\nExpanded adjusted gross margin to 74% and generated adjusted net income1 of $14.7 million for the third quarter 2025\n\n\n\nRaised guidance to deliver between $425 and $428 million in revenue with between 53% to 55% full year growth in exome and genome revenue\n\n\n\nGranted FDA Breakthrough Device Designation for GeneDx ExomeDx™ and GenomeDx™\n\n\n\nLeading the nation in genomic newborn screening (gNBS) as the sole commercial testing provider for new gNBS programs, including the NIH BEACONS initiative and Sunshine Genetics Network\n\n\n\nHosting conference call today at 8:30 a.m. ET\n\n\n\n GAITHERSBURG, Md.--(BUSINESS WIRE)--\nGeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the third quarter of 2025.\n\n\n“GeneDx’s accelerated growth reflects more than business momentum - it’s proof of the profound impact we’re making for families navigating rare disease and the broader transformation underway across healthcare,” said Katherine Stueland, President and CEO of GeneDx. “The FDA’s Breakthrough Device Designation for our ExomeDx™ and GenomeDx™ tests underscores our innovative leadership in delivering faster, more accurate diagnoses when every day matters. Powered by GeneDx Infinity™, we’re helping usher in a new era of proactive, personalized care that begins at birth - advancing precision medicine to improve outcomes and change lives.”\n\n\nThird Quarter 2025 Financial Results (Unaudited)1,2\n\n\nRevenues\n\n\n\nRevenues grew to $116.7 million, an increase of 52% year-over-year.\n\n\n\nExome and genome test revenue grew to $98.9 million, an increase of 65% year-over-year.\n\n\n\nExome and genome volume\n\n\n\nExome and genome test results volume grew to 25,702, an increase of 33% year-over-year.\n\n\n\nExome and genome represented 43% of all tests, up from 33% in the third quarter of 2024.\n\n\n\nGross margin\n\n\n\nAdjusted gross margin expanded to 74%, up from 64% in the third quarter of 2024.\n\n\nGAAP gross margin was 72%.\n\n\n\n\n\n\nOperating expenses\n\n\n\nAdjusted total operating expenses were $71.2 million, representing...